Pfizer has been given a 'Neutral' rating by UBS, with a price target of $31. Trung Huynh, an analyst, stated that there were no unexpected developments in Pfizer's outlook for 2025.
Pfizer is facing changing industry dynamics and investors will be closely watching its performance and strategic initiatives. UBS's rating reflects a cautious stance on Pfizer's future prospects, highlighting the importance of staying informed on upcoming announcements and market trends.